Spojené štáty - angličtina - NLM (National Library of Medicine)

sandoz inc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii - ascorbic acid 80 mg in 4 ml - infuvite pediatric is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. infuvite pediatric is contraindicated in patients who have: infuvite pediatric has not been studied in pregnant women. pregnant women should follow the u.s. recommended daily allowances for pregnancy because their vitamin requirements may exceed those of non-pregnant women. animal reproduction studies have not been conducted with infuvite pediatric (multiple vitamins injection). infuvite pediatric has not been studied in nursing mothers. lactating women may have vitamin requirements that exceed those of non-lactating women. caution should be exercised when infuvite pediatric is administered to nursing mothers. infuvite pediatric is approved for the prevention of vitamin deficiency in pediatric patients up to 11 years

Spojené štáty - angličtina - NLM (National Library of Medicine)

sandoz inc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin 5'-phosphate sodium (unii: 20rd1dzh99) (flavin mononucleotide - unii:7n464ure7e), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), niacinamide (unii: 25x51i8rd4) (niacinamide - unii - infuvite pediatric is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. the physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. infuvite pediatric is contraindicated in patients who have: infuvite pediatric has not been studied in pregnant women. pregnant women should follow the u.s. recommended daily allowances for pregnancy because their vitamin requirements may exceed those of non-pregnant women. animal reproduction studies have not been conducted with infuvite pediatric (multiple vitamins injection). infuvite pediatric has not been studied in nursing mothers. lactating women may have vitamin requirements that exceed those of non-lactating women. caution should be exercised when infuvite pediatric is administered to nursing mothers. infuvite pediatric is approved for the prevention of vitamin deficiency in pediatric patients up to 11 years

Filipíny - angličtina - FDA (Food And Drug Administration)

pedia ogcare inc - paracetamol - suspension (oral drops) - 100mg/ml

Malta - angličtina - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - pertactin, pertussis toxoid, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, diphtheria toxoid, filamentous haemagglutinin, fha, fimbriae types, and, haemophilus influenzae, type b, polysaccharide, polyribosylribitol phosphate, tetanus toxoid - suspension for injection in pre-filled syringe - pertactin 3 µg pertussis toxoid 20 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu poliovirus (inactivated) type 3 (saukett strain) 32 dagu diphtheria toxoid filamentous haemagglutinin (fha) 20 µg fimbriae types 2 and 3 5 µg haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg tetanus toxoid - vaccines

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur msd ltd - human poliovirus type 3 inactivated; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; diphtheria toxoid; haemophilus influenzae type b polysaccharide protein conjugate - suspension for injection

Filipíny - angličtina - FDA (Food And Drug Administration)

xeno pharmaceutical phils inc.; distributor: pedia ogcare inc. - paracetamol - suspension (honeydew melon flavor) - 120mg/ 5ml

Filipíny - angličtina - FDA (Food And Drug Administration)

xeno pharmaceuticals phils. inc.; distributor: pedia ogcare, inc. - salbutamol (as sulfate) , guaifenesin - syrup - 1mg/ 50mg per 5ml

Singapur - angličtina - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - diphtheria toxoid - injection - 15 lf/0.5 ml

Kanada - angličtina - Health Canada

sanofi pasteur limited - pertactin; pertussis toxoid; diphtheria toxoid; tetanus toxoid; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett; haemophilus influenzae type b-prp; tetanus protein; filamentous haemagglutinin; fimbriae - suspension - 3mcg; 20mcg; 15lf; 5lf; 29unit; 7unit; 26unit; 10mcg; 30mcg; 20mcg; 5mcg - pertactin 3mcg; pertussis toxoid 20mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney 29unit; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1 7unit; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett 26unit; haemophilus influenzae type b-prp 10mcg; tetanus protein 30mcg; filamentous haemagglutinin 20mcg; fimbriae 5mcg - vaccines

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - diphtheria toxoid, adsorbed 15 lf u; haemophilus influenzae type b polysaccharide 10ug; pertactin 3ug (adsorbed); pertussis filamentous haemagglutinin 20ug (adsorbed); pertussis fimbriae 2+3 5ug (adsorbed); pertussis toxoid, adsorbed 20ug; polio virus type 1 40 dagu (mahoney, inactivated); polio virus type 2 8 dagu (m e f 1, inactivated); polio virus type 3 32 dagu (saukett, inactivated); tetanus toxoid 20ug (covalently bound to hib prp); tetanus toxoid, adsorbed 5 lf u - suspension for injection - active: diphtheria toxoid, adsorbed 15 lf u haemophilus influenzae type b polysaccharide 10ug pertactin 3ug (adsorbed) pertussis filamentous haemagglutinin 20ug (adsorbed) pertussis fimbriae 2+3 5ug (adsorbed) pertussis toxoid, adsorbed 20ug polio virus type 1 40 dagu (mahoney, inactivated) polio virus type 2 8 dagu (m e f 1, inactivated) polio virus type 3 32 dagu (saukett, inactivated) tetanus toxoid 20ug (covalently bound to hib prp) tetanus toxoid, adsorbed 5 lf u excipient: aluminium phosphate bovine serum albumin formaldehyde glutaral neomycin phenoxyethanol polymyxin b sulfate polysorbate 80 streptomycin water for injection - pediacel is indicated for the primary immunisation of children from 6 weeks of age against diphtheria, tetanus, pertussis, poliomyelitis and invasive haemophilus influenzae type b disease. pediacel® is also indicated for the fourth dose for children from 15 months of age up to 20 months who have been immunised previously with up to three doses of diphtheria, tetanus, pertussis, polio and haemophilus influenzae type b disease vaccines.